Iclepertin

DB19058InvestigationalSmall molecule

Iclepertin is under investigation in clinical trial NCT05211947 (A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study).

Formula / weight: C₂₀H₁₈F₆N₂O₅S · 512.42 g/mol (avg)
Also known as: [5-(Methylsulfonyl)-2-[(1R)-2,2,2-trifluoro-1-methylethoxy]phenyl][(1R,5R)-1-[5-(trifluoromethyl)-3-isoxazolyl]-3-azabicyclo[3.1.0]hex-3-yl]methanone · Methanone, (5-(methylsulfonyl)-2-((1r)-2,2,2-trifluoro-1-methylethoxy)phenyl)((1r,5r)-1-(5-(trifluoromethyl)-3-isoxazolyl)-3-azabicyclo(3.1.0)hex-3-yl)-

Resolves to

Compound

UNIIM43ZDU10DDCAS1421936-85-7

Structure

InChIKeyMYHDQTVHHMSLEF-DDBGAENHSA-NSMILES[H][C@@]12C[C@@]1(CN(C2)C(=O)C1=CC(=CC=C1O[C@H](C)C(F)(F)F)S(C)(=O)=O)C1=NOC(=C1)C(F)(F)F

Targets

P48067SLC6A9

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Iclepertin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account